Wire · opportunities
SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
SpyGlass Pharma announced positive 4-year data from the first-in-human trial of its BIM-IOL System, a drug delivery implant combining a monofocal intraocular lens with sustained-release bimatoprost to reduce intraocular pressure in glaucoma and ocular hypertension patients. The trial showed a 37% IOP reduction, high medication independence, and no product-related adverse events at the 4-year mark.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You now have evidence that sustained drug delivery implants can reduce glaucoma medication dependence for years after cataract surgery. If you develop ophthalmic implants, this trial data opens a clinical pathway for longer-lasting treatments with proven visual acuity outcomes.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics